There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840716, Houston, Texas +1 locations
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04830137
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Register for Updates
A Comparison of Healthcare Provider and Caregiver Perception of Discomfort in Advanced Cancer Patients Who Have a Hypoactive Delirium
NCT05837039
Recruiting
To learn about your feelings as a caregiver about the level of discomfort of patients who have hypoactive delirium (loss of contact and response to reality) and who are at the end of life
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hypoactive Delirium
Register for Updates
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors
NCT06384352
Recruiting
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. Part 3 is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: The University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumors
Register for Updates
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
NCT06455826
Recruiting
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/11/2025
Locations: Baylor College of Medicine- Alkek Eye Center, Houston, Texas
Conditions: Retinitis Pigmentosa 11, Retinal Degeneration, Eye Diseases, Retinal Disease, Retinal Dystrophies
Register for Updates
Helix Research Network
NCT06057181
Recruiting
The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Hermann Health System (genoME), Houston, Texas
Conditions: Genetic Predisposition to Disease, Genetics Disease
Register for Updates
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398
Recruiting
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
03/10/2025
Locations: Ascendis Investigational Site, Houston, Texas
Conditions: Achondroplasia
Register for Updates
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
NCT06146257
Recruiting
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximatel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
NCT06167317
Recruiting
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors * To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumors
Register for Updates
SNV1521 in Participants with Advanced Solid Tumors
NCT06220864
Recruiting
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
NCT06448013
Recruiting
To find the recommended dose of ziftomenib in combination with gemtuzumab ozogamicin and venetoclax that can be given to pediatric participants who have relapsed or refractory AML or MPAL.
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People with Inflammatory Arthritis
NCT06555562
Recruiting
This study is designed to investigate whether non-invasive ultrasound (US) that is optimized for stimulation and can elicit an anti-inflammatory response in people with Inflammatory Arthritis as compared to a sham intervention. The primary endpoint is the change in pro-inflammatory cytokines in blood drawn before and after US. Each participant receives 4 experimental US sessions, one of which is randomly assigned to be placebo.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/10/2025
Locations: UT Health, Houston, Texas
Conditions: Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Register for Updates